This trial evaluates the safety and effectiveness of a new drug, ADA-011, alone and with another drug, to treat certain illnesses. Dose levels are increased to find the best dose.
- Solid Tumors, Adult
2 Primary · 2 Secondary · Reporting Duration: 36 months
3 Treatment Groups
ADA-011 Monotherapy Dose Escalation
1 of 3
ADA-011 Monotherapy Dose Expansion
1 of 3
Combination Therapy Dose Escalation
1 of 3
90 Total Participants · 3 Treatment Groups
Primary Treatment: ADA-011 Monotherapy Dose Escalation · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is the Combination Therapy Dose Escalation procedure known to be innocuous for subjects?
"With limited clinical data of its efficacy and safety, our team at Power gave Combination Therapy Dose Escalation a score of 1 on the scale." - Anonymous Online Contributor
Are new participants being welcomed into this trial presently?
"Indeed, the trial is open for recruitment according to data hosted on clinicaltrials.gov. This research study was initially posted on November 15th 2022 and has been modified most recently on January 6th 2023." - Anonymous Online Contributor
What is the current size of this medical research study?
"Affirmative. Clinicaltrials.gov displays that this medical trial, initially advertised on November 15th 2022, is actively searching for participants to enrol in the study. Two sites are looking to enroll a combined 90 patients into the program." - Anonymous Online Contributor